(Q34661125)

English

Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

bipolar disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mark Weiser

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Shimon Burshtein

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ari A Gershon

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gabriela Marian

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nicolae Vlad

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Iosif G Grecu

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Elena Tocari

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Alexandru Tiugan

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Mihail Hotineanu

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

John M Davis

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

8 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Bipolar Disorders

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

441-447

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Neuroprotective signaling pathways are modulated by adenosine in the anoxia tolerant turtle

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

A rating scale for mania: reliability, validity and sensitivity

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12202

21 January 2018

Identifiers

10.1111/BDI.12202

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34661125&oldid=1959571215"